Stock Scorer

Arrowhead Pharmaceuticals, Inc. (ARWR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 200M 400M 600M Q4 '21: 38.3M Q1 '22: 27.4M Q2 '22: 151.8M Q3 '22: 32.4M Q4 '22: 31.6M Q1 '23: 62.5M Q2 '23: 146.3M Q3 '23: 15.8M Q4 '23: 16.1M Q1 '24: 3.6M Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 2.5M Q2 '25: 542.7M Q3 '25: 27.8M Q4 '25: 256.5M Q1 '26: 264M Q2 '26: 73.7M Q3 '26: 75.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income Quarterly

-300M -150M 0 150M 300M 450M Q4 '21: -64.9M Q1 '22: -63.3M Q2 '22: 41.6M Q3 '22: -72.9M Q4 '22: -83.8M Q1 '23: -42.1M Q2 '23: 48.2M Q3 '23: -102.7M Q4 '23: -108.3M Q1 '24: -136.5M Q2 '24: -126.2M Q3 '24: -176.1M Q4 '24: -162.2M Q1 '25: -161.4M Q2 '25: 381.2M Q3 '25: -165.6M Q4 '25: 44.1M Q1 '26: 40.8M Q2 '26: -141.3M Q3 '26: -170.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-300M -150M 0 150M 300M 450M Q4 '21: -63.4M Q1 '22: -62.9M Q2 '22: 44.4M Q3 '22: -72M Q4 '22: -85.5M Q1 '23: -41.3M Q2 '23: 48.7M Q3 '23: -102.9M Q4 '23: -109.7M Q1 '24: -132.9M Q2 '24: -125.3M Q3 '24: -170.8M Q4 '24: -170.5M Q1 '25: -173.1M Q2 '25: 370.4M Q3 '25: -175.2M Q4 '25: -23.8M Q1 '26: 30.8M Q2 '26: -132.7M Q3 '26: -194.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow Quarterly

-200M 0 200M 400M 600M Q4 '21: -24M Q1 '22: -61.3M Q2 '22: 62.7M Q3 '22: -68.8M Q4 '22: -68.7M Q1 '23: -75.5M Q2 '23: -31.7M Q3 '23: -20.8M Q4 '23: -25.9M Q1 '24: -117.8M Q2 '24: -92.4M Q3 '24: -115.4M Q4 '24: -137.2M Q1 '25: -146.3M Q2 '25: 460.1M Q3 '25: -154.7M Q4 '25: 20.5M Q1 '26: 13.5M Q2 '26: 84.4M Q3 '26: -177.5M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-200M 0 200M 400M 600M Q4 '21: -32.2M Q1 '22: -67.1M Q2 '22: 58M Q3 '22: -78.4M Q4 '22: -101.4M Q1 '23: -114.4M Q2 '23: -59M Q3 '23: -67.4M Q4 '23: -89.8M Q1 '24: -186.5M Q2 '24: -126.5M Q3 '24: -129.9M Q4 '24: -161.5M Q1 '25: -153.8M Q2 '25: 454.8M Q3 '25: -157.1M Q4 '25: 13M Q1 '26: 11.3M Q2 '26: 81.9M Q3 '26: -181.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 101.7M Q3 '20: 101.8M Q1 '21: 102.8M Q2 '21: 103.9M Q3 '21: 104.1M Q1 '22: 104.5M Q2 '22: 107.9M Q3 '22: 105.8M Q1 '23: 106M Q2 '23: 108.1M Q3 '23: 107M Q1 '24: 107.4M Q2 '24: 123.3M Q3 '24: 124.2M Q1 '25: 124.8M Q2 '25: 134.5M Q3 '25: 139M Q1 '26: 140.7M Q2 '26: 142.4M Q3 '26: 143.4M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '21: -1.36 Q1 '22: -1.76 Q2 '22: -1.09 Q3 '22: -1.48 Q4 '22: -1.68 Q1 '23: -1.47 Q2 '23: -1.43 Q3 '23: -1.71 Q4 '23: -1.92 Q1 '24: -2.77 Q2 '24: -4.24 Q3 '24: -4.66 Q4 '24: -5.01 Q1 '25: -5.16 Q2 '25: -1.39 Q3 '25: -1.27 Q4 '25: -0.01 Q1 '26: 1.60 Q2 '26: -2.08 Q3 '26: -2.18 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ARWR: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.